These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 19655335)

  • 1. Drug development costs when financial risk is measured using the Fama-French three-factor model.
    Vernon JA; Golec JH; Dimasi JA
    Health Econ; 2010 Aug; 19(8):1002-5. PubMed ID: 19655335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The price of innovation: new estimates of drug development costs.
    DiMasi JA; Hansen RW; Grabowski HG
    J Health Econ; 2003 Mar; 22(2):151-85. PubMed ID: 12606142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost of drug development: a systematic review.
    Morgan S; Grootendorst P; Lexchin J; Cunningham C; Greyson D
    Health Policy; 2011 Apr; 100(1):4-17. PubMed ID: 21256615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New estimates of drug development costs.
    Frank RG
    J Health Econ; 2003 Mar; 22(2):325-30. PubMed ID: 12606149
    [No Abstract]   [Full Text] [Related]  

  • 5. A dynamic perspective on pharmaceutical competition, drug development and cost effectiveness.
    Refoios Camejo R; McGrath C; Herings R
    Health Policy; 2011 Apr; 100(1):18-24. PubMed ID: 20864202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costing drug development.
    Nat Rev Drug Discov; 2003 Apr; 2(4):247. PubMed ID: 12680358
    [No Abstract]   [Full Text] [Related]  

  • 7. The calculus of cures.
    Kocher R; Roberts B
    N Engl J Med; 2014 Apr; 370(16):1473-5. PubMed ID: 24571723
    [No Abstract]   [Full Text] [Related]  

  • 8. Drug costs: research and development costs: the great illusion.
    Prescrire Int; 2004 Feb; 13(69):32-6. PubMed ID: 15055226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost of innovation in the pharmaceutical industry.
    DiMasi JA; Hansen RW; Grabowski HG; Lasagna L
    J Health Econ; 1991 Jul; 10(2):107-42. PubMed ID: 10113009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risky business--health care finance and the VA.
    Bromley HR
    Physician Exec; 2008; 34(3):42-4, 46-7. PubMed ID: 18605271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What's your real cost of capital?
    McNulty JJ; Yeh TD; Schulze WS; Lubatkin MH
    Harv Bus Rev; 2002 Oct; 80(10):114-21, 130. PubMed ID: 12389465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opinion: development of new drugs is still a risky business.
    Franks B
    N J Med; 2002; 99(1-2):60, 59. PubMed ID: 15326736
    [No Abstract]   [Full Text] [Related]  

  • 13. Objective risk adjustment improves calculated ROI for capital projects.
    Holmes RL; Schroeder RE; Harrington LF
    Healthc Financ Manage; 2000 Dec; 54(12):48-52. PubMed ID: 11141687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Who pays what in drug development.
    Love J
    Nature; 1999 Jan; 397(6716):202. PubMed ID: 9930689
    [No Abstract]   [Full Text] [Related]  

  • 15. Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval.
    Prasad V; Mailankody S
    JAMA Intern Med; 2017 Nov; 177(11):1569-1575. PubMed ID: 28892524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative study on the cost of new antibiotics and drugs of other therapeutic categories.
    Falagas ME; Fragoulis KN; Karydis I
    PLoS One; 2006 Dec; 1(1):e11. PubMed ID: 17183637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The $2.6 billion pill--methodologic and policy considerations.
    Avorn J
    N Engl J Med; 2015 May; 372(20):1877-9. PubMed ID: 25970049
    [No Abstract]   [Full Text] [Related]  

  • 18. Future European health care: cost containment, health care reform and scientific progress in drug research.
    Emilien G
    Int J Health Plann Manage; 1997; 12(2):81-101. PubMed ID: 10173136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capital investment analysis: three methods.
    Gapenski LC
    Healthc Financ Manage; 1993 Aug; 47(8):60-6. PubMed ID: 10145854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Development of new drugs is too expensive].
    Andreasen J
    Ugeskr Laeger; 2003 May; 165(19):1959-60. PubMed ID: 12795066
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.